A pathogenetic link between non-alcoholic fatty liver disease and celiac disease

详细信息    查看全文

• 作者：Ludovico Abenavoli (1)
  Natasa Milic (2)
  Antonino De Lorenzo (3)
  Francesco Luzza (1)
  
• 关键词：Non ; alcoholic fatty liver disease ; Celiac disease ; Intestinal permeability ; Microbiota
• 刊名：Endocrine
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：43
• 期：1
• 页码：65-67
• 全文大小：177KB
• 参考文献：1. P. Angulo, Non-alcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-231 (2002) CrossRef
  2. S. Bellentani, F. Scaglioni, M. Marino et al., Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28, 155-61 (2010) CrossRef
  3. G.A. Garinis, B. Fruci, A. Mazza et al., Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int. J. Obes. 34, 1255-264 (2010) CrossRef
  4. P.H. Green, C. Cellier, Celiac disease. N. Engl. J. Med. 357, 1731-743 (2007) CrossRef
  5. L. Maiuri, C. Ciacci, I. Ricciardelli et al., Association between innate response to gliadin and activation of pathogenic T cells in celiac disease. Lancet 362, 30-7 (2003) CrossRef
  6. A. Vilppula, K. Kaukinen, L. Luostarinen et al., Increasing prevalence and high incidence of celiac disease in elderly people: a population-based study. BMC. Gastroenterol. 9, 49 (2009) CrossRef
  7. U. Volta, Pathogenesis and clinical significance of liver injury in celiac disease. Clin. Rev. Allergy Immunol. 36, 62-0 (2009) CrossRef
  8. C.P. Day, O.F. James, Steatohepatitis: a tale of two “hits- Gastroenterology 114, 842-45 (1998) CrossRef
  9. C.P. Day, Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 26, 1021-028 (2006) CrossRef
  10. S. Prakash, L. Rodes, M. Coussa-Charley et al., Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 5, 1-6 (2011)
  11. J.P. Nolan, The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 52, 1829-835 (2010) CrossRef
  12. M.T. DeMeo, E.A. Mutlu, A. Keshavarzian et al., Intestinal permeation and gastrointestinal disease. J. Clin. Gastroenterol. 34, 385-96 (2002) CrossRef
  13. A. Farhadi, S. Gundlapalli, M. Shaikh et al., Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28, 1026-033 (2008) CrossRef
  14. T.H. Frazier, J.K. DiBaise, C.J. McClain, Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J. Parenter. Enteral. Nutr. 35(5 Suppl), 14S-0S (2011) CrossRef
  15. P. Brun, I. Castagliuolo, V. Di Leo et al., Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G518–G525 (2007) CrossRef
  16. L. Abenavoli, V. Arena, F. Giancotti et al., Celiac disease, primary biliary cirrhosis and helicobacter pylori infection: one link for three diseases. Int. J. Immunopathol. Pharmacol. 23, 1261-265 (2010)
  17. I.R. Korponay-Szabo, T. Halttunen, Z. Szalai et al., In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 53, 641-48 (2004) CrossRef
  18. M.T. Bardella, L. Valenti, C. Pagliari et al., Searching for coeliac disease in patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 36, 333-36 (2004) CrossRef
  19. L. Miele, V. Valenza, G. La Torre et al., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877-887 (2009) CrossRef
  20. A.J. Wigg, I.C. Roberts-Thomson, R.B. Dymock et al., The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206-11 (2001) CrossRef
  21. A.J. Wigg, A.G. Cummins, Reply to Grieco et al. Gut. 49, 596 (2001)
  22. A. Grieco, L. Miele, G. Pignatoro et al., Is coeliac disease a confounding factor in the diagnosis of NASH? Gut 49, 596 (2001) CrossRef
  23. V. Nehra, P. Angulo, A.L. Buchman et al., Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig. Dis. Sci. 46, 2347-352 (2001) CrossRef
  24. O. Loiacono, S. Petta, G. Venezia et al., Anti-tissue transglutaminase antibodies in patients with abnormal liver test: is it always celiac disease? Am. J. Gastroenterol. 100, 2472-477 (2005) CrossRef
  25. A.R. Rahimi, N.E. Daryani, H. Ghofrani et al., The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran. Turk. J. Gastroenterol. 22, 300-04 (2011)
  
• 作者单位：Ludovico Abenavoli (1)
  Natasa Milic (2)
  Antonino De Lorenzo (3)
  Francesco Luzza (1)
  
  1. Department of Health Sciences, University “Magna Gr?cia- Viale Europa, 88100, Catanzaro, Italy
  2. Department of Pharmacy, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia
  3. Department of Neuroscience, Division of Human Nutrition, University “Tor Vergata- Via Montpellier n.1, 00133, Rome, Italy
  

文摘

Non-alcoholic fatty liver disease (NAFLD) has recently been recognized as the leading cause of the abnormalities in the liver function tests in the Western countries. Celiac disease (CD) is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. CD has been reported in 4-3?% of the cases with steatohepatitis, although the pathogenesis of the liver steatosis in CD patients is unclear. Based on the literature data, it can be concluded that the inclusion of serological markers of CD should be a part of the general workup in the patients with steatosis when other causes of the liver disease are excluded and in the patients with NAFLD when metabolic risk factors are not evident.